Overview

The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of vonoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, many studies use vonoprazan instead of common proton pump inhibitor, but almost all use double dose of vonoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 20mg QD of vonoprazan. Therefore, in this study, 20mg QD of vonoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of vonoprazan on Helicobacter pylori.

Eligibility

Patients aged ≥18 years with Hp-positive first sterilization were included in this study.

        Before treatment, the existence of Helicobacter pylori can be confirmed by one or more of
        the following methods: rapid urease test, Hp culture, 13C urea breath test, 14C urea breath
        test and stool Hp antigen test.
        The main exclusion criteria include acute upper gastrointestinal bleeding, active gastric
        or duodenal ulcer, acute gastric or duodenal mucosal lesions, previous eradication
        treatment of Helicobacter pylori, penicillin/furazolidone allergy, surgery that may affect
        gastric acid secretion (upper gastrointestinal resection or vagotomy), Zollinger-Ellison
        syndrome or other hypergastric acid secretion diseases, severe neurological,
        cardiovascular, pulmonary, liver, renal, metabolic, gastrointestinal, urological, etc. Any
        fertile woman must use proper contraception. All subjects provided written informed consent
        before participating in the study.